Calls for papers
-
The FDA has issued new and revised product-specific guidances (PSGs) for a number of OINDPs as of June 3, 2020. The agency also updated its list of planned PSGs for complex generics, adding a number… Read more . . .
-
Dutch vaccine maker Intravacc has announced that it is partnering with Wageningen Bioveterinary Research (WBVR) and Utrecht University on development of an intranasal Newcastle disease virus (NDV) vector vaccine for the prevention of COVID-19 in humans. The company said that… Read more . . .
-
Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed’s Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria… Read more . . .
-
Inhaled drug CDMO Vectura has announced the appointments of Trevor Archbold, Robert Gurley, and Chris Vernall as Business Development Directors, reporting to recently appointed Chief Commercial Officer Mark Bridgewater. Archbold and Vernall will cover Europe;… Read more . . .
-
Vaping startup Respira Technologies has announced the launch of its RespiRx delivery device platform, which the company is aiming at pharmaceutical drug delivery “across the fullest spectrum of pressure and thermo sensitive APIs.” The company,… Read more . . .
-
Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of “resolution of… Read more . . .
-
Altimmune announced that the FDA has approved the company’s IND for a Phase 1/2 clinical trial of its T-COVID intranasal therapy for the treatment of COVID-19, with data expected to be available in the fourth… Read more . . .
-
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa’s AT-301 as a candidate for the treatment of mild COVID-19, and it plans… Read more . . .
-
DPI developer Iconovo announced that the company’s ICOcap capsule-based dry powder inhaler ICOcap is now CE marked for use in clinical trials. The ICOcap inhaler is available from the Stevanato Group, which signed a manufacturing,… Read more . . .
-
Microbion Corporation said that it has received a grant worth up to $11.5 million from global non-profit CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a grant worth up to $5.6 million from the Cystic Fibrosis… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA